SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the adoption and utilization of its SSi Mantra surgical robotic system, underscoring the company's expanding global footprint and the increasing acceptance of robotic-assisted surgery. As of Sept. 8, 2026, the system had been used in 14,103 cumulative procedures, a 79% jump from 7,885 at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168, reflecting accelerating demand across multiple markets.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been employed in more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's strategy to make robotic surgery accessible in both developed and emerging markets.
In addition to its general surgery applications, SS Innovations has made strides in pediatric and telesurgery. As of Aug. 31, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability in high-volume settings.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones are critical for expanding into the U.S. and European markets, which represent significant opportunities for growth. The company's ability to secure these approvals could further accelerate adoption and revenue.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors, the procedure growth and installed base expansion signal strong commercial traction. The upcoming regulatory decisions could serve as catalysts for the stock, as they would open up the largest markets for surgical robotics. The company's focus on affordability and accessibility differentiates it from competitors, potentially allowing it to capture market share in cost-sensitive regions. However, the company faces competition from established players and must continue to demonstrate clinical efficacy and safety to gain widespread adoption.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. To view the full report, visit https://ibn.fm/DJILj.
